Physician profile
Luke E Sebel
NPI 1154718898
$1,833.44
in general payments reported to CMS, 2019-2025
24 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $264 · 2024: $625 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $322.85 | 2025 | Adstiladrin |
| Janssen Biotech, INC. | $270.43 | 2024-2025 | Erleada |
| Procept Biorobotics Corporation | $221.46 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $121.09 | 2024-2025 | Urolift, Barrigel |
| Telix Pharmaceuticals | $110.42 | 2024-2025 | Illuccix |
| Coloplast Corp | $106.16 | 2023-2024 | Titan |
| Boston Scientific Corporation | $75.44 | 2023-2025 | Spaceoar Vue System - 10ml, Ams 700, Axonics |
| Endo USA, INC. | $67.75 | 2024-2025 | Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $54.49 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $53.12 | 2024-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $46.76 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $46.19 | 2023 | Xiaflex |
| Urogen Pharma, INC. | $44.92 | 2025 | |
| Calyxo, INC. | $42.42 | 2025 | Cvac Aspiration System |
| Novartis Pharmaceuticals Corporation | $41.78 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bluewind Medical | $35.38 | 2024 | Revi |
| Verity Pharmaceuticals INC. | $33.87 | 2025 | Tlando |
| Pfizer INC. | $25.87 | 2025 | |
| Olympus America INC. | $22.35 | 2024 | Itind System |
| Astellas Pharma US INC | $21.86 | 2025 | Padcev |
| Accord Healthcare, INC. | $19.48 | 2025 | |
| Angiodynamics, INC. | $17.00 | 2024 | Nanoknife |
| Merck Sharp & Dohme LLC | $16.33 | 2023 | Keytruda |
| Immunitybio, INC. | $16.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Sebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.